Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-057100
Filing Date
2026-05-07
Accepted
2026-05-07 16:05:22
Documents
81
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20260331x10q.htm   iXBRL 10-Q 1764800
2 EX-31.1 crvs-20260331xex31d1.htm EX-31.1 11826
3 EX-31.2 crvs-20260331xex31d2.htm EX-31.2 11764
4 EX-32.1 crvs-20260331xex32d1.htm EX-32.1 11817
5 GRAPHIC crvs-20260331x10q007.jpg GRAPHIC 52299
6 GRAPHIC crvs-20260331x10q008.jpg GRAPHIC 65247
7 GRAPHIC crvs-20260331x10q009.jpg GRAPHIC 53164
8 GRAPHIC crvs-20260331x10q010.jpg GRAPHIC 49895
9 GRAPHIC crvs-20260331x10q011.jpg GRAPHIC 48513
10 GRAPHIC crvs-20260331x10q012.jpg GRAPHIC 67674
  Complete submission text file 0001104659-26-057100.txt   8113150

Data Files

Seq Description Document Type Size
11 EX-101.SCH crvs-20260331.xsd EX-101.SCH 42656
12 EX-101.CAL crvs-20260331_cal.xml EX-101.CAL 53897
13 EX-101.DEF crvs-20260331_def.xml EX-101.DEF 208112
14 EX-101.LAB crvs-20260331_lab.xml EX-101.LAB 402958
15 EX-101.PRE crvs-20260331_pre.xml EX-101.PRE 327842
85 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20260331x10q_htm.xml XML 1190239
Mailing Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 26953097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)